Context Although the widespread use of prostate-specific antigen (PSA) has led to an early
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …

The development of more specific biomarkers for prostate cancer and/or high‐risk prostate
cancer is necessary, because the prostate‐specific antigen test lacks specificity for the …

Background To reduce overdiagnosis and overtreatment, a test is urgently needed to detect
clinically significant prostate cancer (PCa). Objective To develop a multimodal model …

Cancer-secreted, extracellular vesicle (EV)–encapsulated miRNAs enable cancer cells to
communicate with each other and with noncancerous cells in tumor pathogenesis and …

Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of
cancer-related death. Early detection of prostate cancer is largely determined by a widely …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Early detection of prostate cancer (PC) is largely carried out using assessment of prostate-
specific antigen (PSA) level; yet it cannot reliably discriminate between benign pathologies …

Growing bodies of evidence have demonstrated that the identification of prostate cancer
(PCa) biomarkers in the patients' blood and urine may remarkably improve PCa diagnosis …

To better understand the impact of chromatin structure on regulation of the prostate cancer
transcriptome, we develop high-resolution chromatin interaction maps in normal and …

Abstract Treatment of prostate cancer (PC) by androgen suppression promotes the
emergence of aggressive variants that are androgen receptor (AR) independent. Here we …